Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

TIRUCHY: From June 4, all 84 primary health centres (PHCs) in the district, including those under the corporation, will ...

(Reuters) -Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

Eucalyptus oil was first used by Aboriginal Australians, who crushed the leaves for their antiseptic properties or steamed ...

Topline results were announced from two phase 3 trials evaluating itepekimab, an anti-interleukin-33 monoclonal antibody, in former smokers with inadequately controlled chronic obstructive pulmonary ...

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the classic male presentation.

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...